Compare FRPH & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRPH | PEPG |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.3M | 440.0M |
| IPO Year | 1995 | 2022 |
| Metric | FRPH | PEPG |
|---|---|---|
| Price | $23.28 | $5.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 41.7K | ★ 721.3K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $41,774,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $148.00 | ★ N/A |
| Revenue Growth | ★ 0.65 | N/A |
| 52 Week Low | $21.68 | $0.89 |
| 52 Week High | $29.86 | $7.80 |
| Indicator | FRPH | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 40.37 | 47.02 |
| Support Level | $23.10 | $4.36 |
| Resistance Level | $24.61 | $6.81 |
| Average True Range (ATR) | 0.50 | 0.59 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 19.27 | 35.87 |
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.